Abstract 211P
Background
Chronotherapy is a drug intervention at specific times of the day to optimize efficacy and minimize adverse effects. Although chronochemotherapy has been proven to be effective in solid tumors, its value in hematologic malignancy remains unknown. In this study, we tried to identify a chronotherapeutic effect and underlying mechanism of immunochemotherapy in diffuse large B cell lymphoma (DLBCL) patients.
Methods
We performed chronotherapeutic analysis using two cohorts of DLBCL patients undergoing chemotherapy with a dichotomized schedule (morning or afternoon) at a daycare chemotherapy center. The effect of the chronotherapeutic schedule of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on survival and drug tolerability were evaluated in a survival cohort (n=210) and an adverse event cohort (n=129), respectively. Analysis of ∼14,000 healthy subjects was followed to identify the circadian variation in hematologic parameters.
Results
In the survival cohort, both progression-free survival (PFS) and overall survival (OS) of female, but not male, patients were significantly shorter when patients received chemotherapy mostly in the morning (PFS hazard ratio [HR] 0.357; p=0.033 and OS HR 0.141; p=0.032). Consistent with this, the dose intensity of R-CHOP was reduced in female patients in the adverse event cohort (cyclophosphamide 10%; p=0.002, doxorubicin 8%; p=0.002 and rituximab 7%; p=0.003). This reduced dose intensity was mainly attributable to infection and neutropenic fever. In healthy subjects, we found that white blood cell count (WBC) and absolute neutrophil count (ANC) of females were lowest in the morning with exaggerated diurnal fluctuation, which potentially explains the reduced survival and serious adverse effects in female patients receiving morning treatment.
Conclusions
Administration of R-CHOP in the morning reduces the tolerability of chemotherapy and negatively affects the survival outcome of female DLBCL patients, which may be attributable to the diurnal variation of specific hematologic parameters.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Seoul National University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
196P - Short course brachytherapy in locally advanced cervical cancer: Safety and response rate
Presenter: Maryam Garousi
Session: Poster viewing 03
197P - The risk of uterine cervical cancer in inflammatory bowel disease: An updated systematic review and meta-analysis
Presenter: Hee Man Kim
Session: Poster viewing 03
198P - Geographic and demographic access to brachytherapy in India, with a special emphasis on gynaecological cancers
Presenter: Abhishek Krishna
Session: Poster viewing 03
199P - Prevalence of cervical cancer in Uzbekistan: A population based study
Presenter: Sayde Djanklich
Session: Poster viewing 03
200P - A retrospective institutional analysis on gynecological malignant mixed Mullerian tumors
Presenter: Monik Patel
Session: Poster viewing 03
201P - Immunotherapy in advanced mismatch repair deficiency endometrial cancer: A real-world single center experience
Presenter: Amit Rauthan
Session: Poster viewing 03
203TiP - Autophagy as a target for therapy in ovarian cancer: A phase II randomized trial with biomarker correlation (ATOC Trial)
Presenter: Luxitaa Goenka
Session: Poster viewing 03
210P - Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays
Presenter: Lei Chen
Session: Poster viewing 03